Free Trial
NASDAQ:TCRT

Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

Alaunos Therapeutics logo
$1.98 -0.04 (-1.98%)
(As of 04:26 PM ET)

About Alaunos Therapeutics Stock (NASDAQ:TCRT)

Key Stats

Today's Range
$1.95
$2.02
50-Day Range
$2.00
$3.94
52-Week Range
$1.95
$32.85
Volume
21,807 shs
Average Volume
16,299 shs
Market Capitalization
$3.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Alaunos Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
0th Percentile Overall Score

TCRT MarketRank™: 

Alaunos Therapeutics scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Alaunos Therapeutics.

  • Percentage of Shares Shorted

    9.59% of the float of Alaunos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Alaunos Therapeutics has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Alaunos Therapeutics has recently increased by 1.22%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Alaunos Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Alaunos Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.59% of the float of Alaunos Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Alaunos Therapeutics has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Alaunos Therapeutics has recently increased by 1.22%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Alaunos Therapeutics this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Alaunos Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.11% of the stock of Alaunos Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 27.72% of the stock of Alaunos Therapeutics is held by institutions.

  • Read more about Alaunos Therapeutics' insider trading history.
Receive TCRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRT Stock News Headlines

Alaunos Therapeutics (NASDAQ:TCRT) Trading 1.5% Higher - Here's Why
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
See More Headlines

TCRT Stock Analysis - Frequently Asked Questions

Alaunos Therapeutics' stock was trading at $10.6050 at the start of the year. Since then, TCRT stock has decreased by 81.0% and is now trading at $2.01.
View the best growth stocks for 2024 here
.

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) announced its earnings results on Wednesday, August, 14th. The company reported ($0.71) earnings per share for the quarter.

Alaunos Therapeutics shares reverse split before market open on Thursday, July 18th 2024. The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alaunos Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/14/2024
Today
11/08/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TCRT
Employees
40
Year Founded
N/A

Profitability

Net Income
$-35,140,000.00
Pretax Margin
-318,833.31%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.93 per share

Miscellaneous

Free Float
1,519,000
Market Cap
$3.17 million
Optionable
Optionable
Beta
-0.49
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:TCRT) was last updated on 11/8/2024 by MarketBeat.com Staff
From Our Partners